Virtus ETF Advisers’s TG Therapeutics TGTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-11,393
| Closed | -$343K | – | 765 |
|
|
2024
Q4 | $343K | Sell |
11,393
-8,258
| -42% | -$237K | 0.14% | 209 |
|
|
2024
Q3 | $460K | Hold |
19,651
| – | – | 0.21% | 187 |
|
|
2024
Q2 | $350K | Buy |
19,651
+14,836
| +308% | +$237K | 0.17% | 199 |
|
|
2024
Q1 | $73.2K | Sell |
4,815
-328
| -6% | -$5.22K | 0.04% | 403 |
|
|
2023
Q4 | $87.8K | Buy |
5,143
+1,509
| +42% | +$17.5K | 0.06% | 409 |
|
|
2023
Q3 | $30.4K | Sell |
3,634
-367
| -9% | -$5.12K | 0.02% | 428 |
|
|
2023
Q2 | $99.4K | Sell |
4,001
-7,053
| -64% | -$182K | 0.06% | 384 |
|
|
2023
Q1 | $166K | Sell |
11,054
-4,254
| -28% | -$64.6K | 0.09% | 316 |
|
|
2022
Q4 | $181K | Sell |
15,308
-11,827
| -44% | -$85.8K | 0.09% | 322 |
|
|
2022
Q3 | $161K | Buy |
27,135
+200
| +0.7% | +$1.31K | 0.06% | 343 |
|
|
2022
Q2 | $114K | Buy |
26,935
+16,994
| +171% | +$106K | 0.04% | 399 |
|
|
2022
Q1 | $95K | Sell |
9,941
-595
| -6% | -$6.89K | 0.04% | 311 |
|
|
2021
Q4 | $200K | Buy |
10,536
+4,987
| +90% | +$129K | 0.08% | 210 |
|
|
2021
Q3 | $185K | Sell |
5,549
-291
| -5% | -$9K | 0.08% | 290 |
|
|
2021
Q2 | $227K | Sell |
5,840
-1,028
| -15% | -$40.4K | 0.09% | 256 |
|
|
2021
Q1 | $331K | Buy |
6,868
+125
| +2% | +$6.01K | 0.14% | 222 |
|
|
2020
Q4 | $351K | Sell |
6,743
-11,178
| -62% | -$378K | 0.15% | 169 |
|
|
2020
Q3 | $480K | Sell |
17,921
-2,461
| -12% | -$56.6K | 0.25% | 141 |
|
|
2020
Q2 | $397K | Sell |
20,382
-15,224
| -43% | -$245K | 0.19% | 199 |
|
|
2020
Q1 | $350K | Sell |
35,606
-5,183
| -13% | -$65.5K | 0.14% | 208 |
|
|
2019
Q4 | $453K | Buy |
40,789
+5,986
| +17% | +$45.5K | 0.07% | 216 |
|
|
2019
Q3 | $195K | Sell |
34,803
-1,938
| -5% | -$13.5K | 0.04% | 256 |
|
|
2019
Q2 | $318K | Sell |
36,741
-17,202
| -32% | -$130K | 0.07% | 200 |
|
|
2019
Q1 | $434K | Sell |
53,943
-7,614
| -12% | -$41.2K | 0.92% | 33 |
|
|
2018
Q4 | $252K | Buy |
61,557
+27,134
| +79% | +$135K | 0.04% | 157 |
|
|
2018
Q3 | $193K | Sell |
34,423
-24,599
| -42% | -$281K | 0.02% | 196 |
|
|
2018
Q2 | $776K | Sell |
59,022
-30,898
| -34% | -$425K | 0.69% | 47 |
|
|
2018
Q1 | $1.28M | Buy |
89,920
+48,087
| +115% | +$615K | 1.11% | 13 |
|
|
2017
Q4 | $343K | Buy |
41,833
+12,380
| +42% | +$108K | 0.43% | 102 |
|
|
2017
Q3 | $349K | Buy |
29,453
+2,694
| +10% | +$30.7K | 0.05% | 122 |
|
|
2017
Q2 | $269K | Sell |
26,759
-29,783
| -53% | -$333K | 0.04% | 138 |
|
|
2017
Q1 | $659K | Buy |
56,542
+5,420
| +11% | +$38.9K | 0.12% | 88 |
|
|
2016
Q4 | $238K | Buy |
51,122
+15,825
| +45% | +$92.8K | 0.07% | 156 |
|
|
2016
Q3 | $273K | Hold |
35,297
| – | – | 0.13% | 108 |
|
|
2016
Q2 | $214K | Buy |
35,297
+11,311
| +47% | +$91.9K | 0.16% | 129 |
|
|
2016
Q1 | $204K | Buy |
+23,986
| New | +$210K | 0.28% | 79 |
|
Other funds holding TGTX
SCM
Virtus ETF Advisers's TGTX Position: Q1 2025 in Review
Virtus ETF Advisers sold out of TG Therapeutics (TGTX) in Q1 2025, closing a stake of 11,393 shares — an estimated $343K sold.
Virtus ETF Advisers first reported a position in TGTX in Q1 2016 and held it in 36 quarters. The position peaked at $1.28M in Q1 2018. 376 funds tracked by Wall St. Rank hold TGTX as of Q1 2025.
- Virtus ETF Advisers reported no remaining TG Therapeutics position as of Q1 2025 after selling out during the quarter.
- Virtus ETF Advisers sold 11,393 TG Therapeutics shares in Q1 2025, an estimated $343K.
- Virtus ETF Advisers first reported a position in TG Therapeutics in Q1 2016 and held it in 36 quarters.
- Virtus ETF Advisers's TG Therapeutics position peaked at $1.28M in Q1 2018.
- 376 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2025.
Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.